Wall Street Trader schreef op 10 juli 2020 14:11:
Stifel Galapagos
(Hold) PT
$193Galapagos downgraded to Hold from Buy at Stifel.
Stifel analyst Derek Archila downgraded Galapagos (GLPG) to Hold from Buy with a price target of $193, down from $298, after taking over coverage of the name.
The stock's setup is unfavorable stock ahead of filgotinib approval in rheumatoid arthritis as there is a low chance of it receiving a "meaningfully differentiated label," Archila tells investors in a research note.
The analyst is also cautious on Gilead (GILD) and Galapagos' ability to deliver filgotinib sales ahead of consensus estimates between 2020 and 2025. He also doesn't see any major, near-term catalysts from the pipeline.
The analyst comments "Our downgrade is predicated on:
(1) an unfavorable stock setup ahead of filgotinib US/EU approval in rheumatoid arthritis (RA) as we think the chance of it receiving a meaningfully differentiated label within the JAK class is low;
(2) we are cautious on GILD/GLPG's ability to deliver filgotinib sales ahead of consensus estimates between 2020-2025 which to us seem high; and
(3) while we are positive on GLPG's pipeline and its long-term prospects, we don't see any major, near-term catalysts from the pipeline that would sufficiently offset our commercial concerns. While there is a lot to like here given GLPG's meaningful cash position and robust R&D engine, we would seek a better entry point."